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Abstract
Cystic fibrosis is the most common and best known genetic disease involving a defect in
transepithelial Cl- transport by mutations in the CF gene on chromosome 7, which codes for the
cystic fibrosis transmembrane conductance regulator protein (CFTR). The most serious symptoms
are observed in the lungs, augmenting the risk of bacterial infection. The objective of this review
was to describe the bacterial pathogens colonizing patients with cystic fibrosis. A systematic search
was conducted using the international bibliographic databanks SCIELO, HIGHWIRE, PUBMED,
SCIRUS and LILACS to provide a useful and practical review for healthcare workers to make them
aware of these microorganisms. Today, B. cepacia,  P. aeruginosa and  S. aureus are the most
important infectious agents in cystic fibrosis patients. However, healthcare professionals must pay
attention to emerging infectious agents in these patients, because they represent a potentially
serious future problem. Therefore, these pathogens should be pointed out as a risk to these
patients, and hospitals all over the world must be prepared to detect and combat these bacteria.
Introduction
Cystic fibrosis (CF) is the most common autosomal
genetic disease in North America, affecting 1:2000 Cauca-
sian individuals [1]. This disease is caused by mutations
affecting the cystic fibrosis conductance regulator protein
(CFTR) and is characterized by chronic lung malfunction,
pancreatic insufficiency and high levels of chloride in
sweat. Its high mortality index is evident when lung and
spleen are affected, but other organs can also be affected.
The persons affected die by progressive bronchiectasis and
chronic respiratory insufficiency [2,3]. This disease affects
persons without distinction of age or sex but can be
asymptomatic in a great number of cases [3]. Failure of
innate defense mechanisms and the lack of mucocilliary
clearance in the airways stimulate primary and recurrent
bacterial infections, blockage of airways, inflammation
and chronic bacterial infections [4,5].
During the first decade of life of CF patients, Staphylococcus
aureus and Hemophilus influenzae are the most common
bacteria isolated from the sputum, but in the second and
third decade of life, Pseudomonas aeruginosa is the preva-
lent bacteria. In Germany, analysis of the sputum from CF
patients during a period of 12 months showed the pres-
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ence of P. aeruginosa in 50% of these individuals, S. aureus
in 63.3%, Haemophilus influenzae in 16.6%, Stenotropho-
monas maltophilia in 15% and nontuberculous Mycobacte-
ria (NTM) in 13.3% [6].
Due to this succession of bacterial populations in CF
patients and due to the importance of these pathogens in
prognosis, the objective of this article was to review and
identify known and emerging bacterial pathogens associ-
ated with pulmonary problems and involved with cystic
fibrosis. For this objective, a systematic search was con-
ducted using the international bibliographic databanks
SCIELO, HIGHWIRE, PUBMED, SCIRUS and LILACS. The
uniterms Cystic fibrosis, infection and antibiotic therapy
were used in a retrospective search between 1990 to 2007.
Any articles with this theme, reporting bacterial pathogen
associated with CF patients with no distinction of sex and
age were selected and only the articles describing patho-
gens and the antibiotic therapy were really used.
Bacterial pathogens associated with pulmonary risk
Major pathogens
Mycobacterium sp
The nontuberculous Mycobacteria (NTM) are a group of
microorganisms that is very common in chronic pulmo-
nary diseases. The increase in the life expectancy of CF
patients has also increased the prevalence of Mycobacteria
in the CF population [7]. The clinical impact of these
microorganisms in CF patients is unclear, because Oliver
et al. [8] found that CF patients infected with NTM,
observed for 15 months, did not show a decline in respi-
ratory function. These microorganisms were isolated from
older CF patients, all of them with perfect respiratory
function, and were associated with a high frequency of S.
aureus and a low one of P. aeruginosa when compared with
patients without NTM, indicating that the presence of
these bacteria may be taken as a good prognostic sign [9].
The most common NTM infecting CF patients are Myco-
bacterium abscessus, Mycobacterium avium, and Mycobacte-
rium intracellulare [6], but Sermet-Gaudelus et al. [10]
identified other NTM from CF patients, including M. for-
tuitum, M. gordonae and M. kansasii. Today, the NTM more
likely associated with the disease is Mycobacterium absces-
sus [11]. The identification of the causal species of NTM is
essential and requires genetic techniques [12]. Treatment
depends on the mycobacterial species. For M. avium, com-
bined therapy with rifampicin, clarythromycin and
ethambutol must be extended 12 months after negativa-
tion. M. abscessus infection is particularly resistant to
therapy. Usual treatment is a one month course of intra-
venous imipenem or cefoxitin plus amikacin followed by
oral clarithromicin plus ethambutol for at least 12
months after negativation. In case of local lesions, surgery
is an option [12].
Staphylococcus aureus
Usually, this is the first pathogen to infect and colonize
the airways of CF patients, being the most common path-
ogen [13]. This microorganism is prevalent in children
and may cause epithelial damage, opening the way to the
adherence of other pathogens such as Pseudomonas aerugi-
nosa [14]. However, other studies indicate that S. aureus is
a co-infective pathogen associated with P. aeruginosa.
Together, the inflammatory process is more intense due
the additive effect of these two pathogens [15]. Before the
use of antibiotics in the treatment of infections, S. aureus
was the causative agent of several deaths in children with
CF. Today, this risk is not so serious, but CF patients not
given the correct antibiotic therapy show a higher preva-
lence of S. aureus in the nasal epithelium when compared
to treated patients [16]. About the prevalence of this path-
ogen, the same strain of S. aureus remains in the patient
for 1–2 years [17].
Methicillin-resistant  S. aureus (MRSA) has become a
major nosocomial pathogen with a progressive increase in
prevalence also in CF populations. The acquisition of
MRSA occurred only in adulthood [18]. In Europe, the
spread of MRSA varies widely among centers, ranging
from 5 to 14% [19]. MRSA is a major pathogen in the hos-
pital setting causing serious infections that usually present
multiresistance to many antibiotics. Moreover, the
increased frequency of this organism in the community,
especially with carriage of virulence factors, including the
presence of the virulence marker pvl, is a matter of concern
[20,21].
Small colony variants (SCVs) of S. aureus constitute a bac-
terial population with distinctive phenotypic traits of S.
aureus populations from CF patients [22]. These popula-
tions are involved with the colonization of older patients
[23], but Sadowska et al. [24] isolated these strains from
children between 1.5 and 9 years old with a SVR preva-
lence of 31.7%.
Pseudomonas aeruginosa
P. aeruginosa is an oxidase-positive Gram-negative motile
rod [25]. Vonberg & Gastmeier [26] showed that this bac-
terium colonizes CF patients in more than 50% of cases.
This bacterium is a part of the normal microbial popula-
tion of the respiratory tract, where it is an opportunistic
pathogen in CF patients. This is more prevalent in adult
CF patients, as infection has been shown in 20% CF
patients 0–2 years old while in 81% in adult groups (>18
years old) [27]. Aaron et al. [28] showed that all CF
patients with chronic infections and older than 16 years
are infected with P. aeruginosa, but Burns et al. [29] found
that 97.5% of children had P. aeruginosa. The capacity of
this bacterium to develop biofilm is a characteristic thatInternational Archives of Medicine 2008, 1:24 http://www.intarchmed.com/content/1/1/24
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allows it to survive for very long periods in the lungs of CF
patients [30].
Isolated from P. aeruginosa can be differentiated in terms
of its morphotypes, including mucoid, not mucoid and
those with biofilm, which vary their patterns of suscepti-
bility to antibiotics. This differentiation causes several
problems in the treatment, because is necessary identify
the morphotype to choose the treatment strategy [31,32].
Burkholderia ssp
Burkholderia cepacia complex (BCC) is a complex of Gram-
negative rod, aerobic, mesophilic and chemoorgano-
trophic [33]. This is a bacterial complex with nine
genomic species (genomovars) [34,35]: genomovar I (B.
cepacia), II (B. multivorans), III (B. cenocepacia), IV (B. sta-
bilis), V (B. vietnamiensis), VI (B. dolosa), VII (B. ambifaria),
VIII (B. anthina), IX (B. pyrrocinia) [35,36].
Infected CF patients show high levels of BCC in the sali-
vary fluid, indicating the possibility of indirect transmis-
sion by kissing and sexual contact [36], but the
transmission rates, prognosis and mortality are distinctly
characteristic for each genomovar, as the treatment strate-
gies[33,37]. Because the difficulties in the culture and
identification of genomovar, this is one of the most
important opportunistic bacterial pathogens of CF
patients [38,39]. Other bacteria the same genus Burkholde-
ria, as Burkholderia gladioli and Burkholderia pseudomallei,
which are distinct from the Burkholderia cepacia complex
have also been reported in patients with cystic fibrosis
[40-42]. Members of B. cepacia complex are very resistant
to antibiotic therapy because its genome is very plastic
and suffers several mutations and adapts itself, making it
a hard challenge for treatment. Its resistance is mainly due
the production of enzymes with capacity to inactivate the
substances used in the treatment [43]. By this fact., the
accuracy and fast detection of this bacterium are essential
to evaluate risks, prognostics and epidemiology of cystic
fibrosis [35].
Minor pathogens
Achromobacter xylosoxidans
This bacterium is a Gram-negative rod, anaerobic, motile,
oxidase and catalase positive and lactose non-fermenta-
tive. It is usually distributed in the environment, but can
be a human pathogen causing bacteremia, meningitis and
pneumonia [44]. This is a pathogen with a growing inci-
dence in CF patients and a high coinfection rate with P.
aeruginosa [45,46].
Inquilinus limosus
Coenye et al. [47] in 2002 isolated 8 strains from airway
secretions of CF patients in the United States, that were
identified as a new genus called Inquilinus, belonging to α-
proteobacteria and further identified as I. limosus. This
bacterium is a mesophilic Gram-negative rod, non-spore
forming. Due to its recent characterization, we have little
knowledge about its natural habitat, prevalence and path-
ogenicity, but CF patients infected with this bacterium
have been identified in hospitals in France, Spain and
Germany [48,49].
Ralstonia sp
These bacteria are Gram-negative and non-fermentative
rods, and little is known about the natural occurrence and
the pathogenicity of bacteria from the genus Ralstonia,
mainly due to their difficult identification, where they are
usually misidentified as P. fluorescens or a member of the
Burkholderia cepacia complex [50-54].
Reports indicate a low prevalence of pathogen from this
genus in CF patients, but Coenye et al. [52] showed the
permanence of this pathogen in the sputum of CF patients
for more than 20 months.
Pandoraea apista
This is a Gram-negative and non-fermentative bacterium
that over the years has shown a growing isolation fre-
quency among CF patients, representing a possible emerg-
ing pathogen in these patients [55,56]. Atkinson et al. [57]
analyzed sputum cultures from 2 adult CF patients (30
and 36 years old, respectively), and found both colonized
by this bacteria and coinfected with P. aeruginosa. This
finding is very important due to the fact that these patients
are first infected with P. aeruginosa, indicating that the lat-
ter pathogen may act as a starting point for P. apista infec-
tion.
Streptococcus pneumoniae
This microorganism is considered a transient pathogen in
CF patients [58], mainly isolated from young CF patients
[59]. The incidence is 5.5% in CF patients 12 and younger,
but in children without the disease the frequency is 50%
[60].
Stenotrophomonos maltophilia
This is a Gram-negative and non-fermentative rod that is
frequently isolated from hospitals [61,62]. S. maltophilia is
a pathogen of CF patients with a very constant incidence
[63]. Goss et al. [62] observed that patients with S. mal-
tophilia were older, showing a high rate of prior co-infec-
tion with P. aeruginosa and B. cepacia, but the prevalence
of this pathogen in CF patients has been growing in the
last years [64].
Haemophilus influenzae
This bacterium usually infects younger CF patients. In Bra-
zil, 20.4% of CF children between 6 and 12 years old are
infected by H. influenzae [65]. This bacterium undergoesInternational Archives of Medicine 2008, 1:24 http://www.intarchmed.com/content/1/1/24
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hyper-mutation, which can be related to its resistance to
antibiotics, making treatment more difficult [66].
Bordetella bronchiseptica
This is a Gram-negative coccobacillus, non spore-forming,
strictly anaerobic, and catalase and coagulase positive
[67]. This bacterium is part of the microbiota of the upper
respiratory tract of many animals [68]. Magalhães et al.
[67], reported the presence of it in a 27- year-old CF
patient associated with S. aureus, which can be a potential
zoonotic infectious agent, aggravating the CF patient situ-
ation.
Treatment
Cystic fibrosis is characterized by chronic pulmonary
infection with acute pulmonary exacerbation (APEs),
where antibiotic therapy is necessary against opportunis-
tic infections [69].
Previous studies have indicated that the presence of
mucoidal P. aeruginosa was the most important risk factor
for pulmonary deterioration [70,71]. By this fact, several
article indicating method to control de colonizing patho-
gens in CF patients use P. aeruginosa as a microbial
marker.
Gentamicin and tobramycin are recognized as standard
antibiotics for the treatment of CF patients infected with
Pseudomonas aeruginosa. Mulheran et al. [72] observed a
higher utilization of gentamicin and tobramycin by pedi-
atric patients and adults respectively. However, the
authors make note of the greater cochleotoxic risk associ-
ated with gentamicin. Depending on the administration
and dose used, tobramycin can be more or less efficient
[73]. When this drug was used in a liposomal formulation
and delivered as an aerosol, the drug bioavailability in
pulmonary tissue and its effectiveness enhance [74,75].
Tests with animals have shown the augmentation of the
amykacin concentration in the lung against Pseudomonas
aeruginosa, when the drug is administered by ultrasonic
nebulization or intravenously, but these levels decrease
after the second administration [76].
Antibiotic combinations against P aeruginosa, such as the
use of polymyxins combined with a β-lactamic are useful
in antipseudomonial therapy, as shown in the work of
Dong & Chung-Dar [77].
Azithromycin displays interesting therapeutic results in
the treatment of CF patients infected with P aeruginosa.
Wagner  et al. [78] reported that azithromycin inhibits
80% of protein synthesis in P aeruginosa PAO1, affecting
bacterial growth and the expression/exportation of prod-
ucts that stimulates the immune system such as pyocy-
anin.
Other point of discussion is the objective of the treatment
of P aeruginosa infection: total eradication, using heavy
doses of antibiotics with adverse symptoms, or the man-
agement of the infection, with a higher risk to develop the
resistance? Few years ago, the eradication of chronic P.
aeruginosa infection was considered impossible [79], but
Ho et al. [80] e Pitt et al. [81] showed that new popula-
tions of P. aeruginosa (after eradication) were different of
the first ones and more sensitive to the antibiotics, show-
ing that persistent populations of P. aeruginosa in the air-
way would increase the antibiotic resistance with time
because of prolonged exposure to antibiotics, as in the
case of management, indicating the eradication as the
most interesting strategy.
For other microorganisms such as B. cepacia, commonly
resistant to several antimicrobial drugs used by CF
patients, the better treatment choice is a drug combina-
tion. Combinations of two antibiotics from different
classes such as meropenem-minocycline, meropenem-
amikacin and meropenem-ceftazidime or three different
antibiotics such as tobramycin, meropene and an addi-
tional antibiotic were more effective than the use of any
antibiotic alone [78]. Similar results were observed
against P. aeruginosa by Dong et al. [77] who showed that
the better treatment is the combination of meropenem/
tobramicin or ceftazidime/tobramicin.
However, new therapeutic perspectives are needed, such
as from the work of Zhang et al. [82] who evaluated the in
vitro effectiveness of 150 antimicrobial peptides in multi-
drug resistant strains of P. aeruginosa, Stenotrophomonas
maltophilia, Achromobacter xylosoxidans and S. aureus. A bet-
ter activity was observed for several peptides compared to
most of the antibiotics used in the clinic. Similar results
were obtained by Etienne et al. [83] who used defensins
and observed a drastic reduction in bacterial growth.
The quality of life and life expectancy of CF patients have
improved considerably as a result of the control of bron-
chopulmonary bacterial colonization and acute infectious
exacerbations [82-85].
These reports indicate the necessity for more research into
the discovery and rational design of new antibacterial
drugs that will be more efficient in combating infections
in cystic fibrosis patients. However, the use must be well
defined. Our search indicates that the combination of 2 or
more antibiotics may represent an interesting alternative
in the CF treatment, colonized for any bacterial pathogen.International Archives of Medicine 2008, 1:24 http://www.intarchmed.com/content/1/1/24
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Other point of interest is the indication of aerosolized and
biofilm-inhibitory drugs may control and avoid the colo-
nization of the respiratory tract by several pathogens cited
in this study. Maybe, using this several approaches, we
will maximize the control of the colonizers and the infec-
tions that affect the CF patients.
Conclusion
Several factors affect transmission, such as the type of bac-
terial strain, the immune state of the patient and the use
of contaminated medical equipment. Therefore, all CF
patients infected or colonized the major pathogens cited
in this article must be isolated in a single room because
they represent sources for nosocomial transmission of the
microorganism to other patients during the treatment
[17,55].
Although the epidemiology of bacterial pathogens in CF
patients has become more complex, the life expectancy of
these patients continues to increase. This has led to a bet-
ter control of the transmission of these pathogens by the
separation of adults and children with CF in different
treatment centers. Furthermore, the utilization of basic
preventive guidelines (hand washing and use of masks,
gloves and protectors), combined with disinfection tech-
niques to be applied at home or hospital make control
easier. These precautions help reduce the impact of infec-
tions in CF patients. In addition, educational programs to
support administrative measures, guidelines for the con-
trol of nosocomial infections and the assistance to health-
care workers and to the families of the patients to show
the importance of these measures are essential tools for
blocking the transmission of these bacterial pathogens to
CF patients.
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